These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9265106)

  • 21. Drugs in development for Alzheimer's disease.
    Miller CA
    Geriatr Nurs; 1993; 14(6):329-30. PubMed ID: 8262443
    [No Abstract]   [Full Text] [Related]  

  • 22. Dementia.
    Warner J; Butler R; Arya P
    Clin Evid; 2004 Jun; (11):1250-77. PubMed ID: 15652059
    [No Abstract]   [Full Text] [Related]  

  • 23. Vitamin E for Alzheimer's disease?
    Simonson W
    Geriatr Nurs; 2014; 35(2):147-8. PubMed ID: 24703434
    [No Abstract]   [Full Text] [Related]  

  • 24. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
    Fillit H; Cummings J
    Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonsedating treatments for Alzheimer's patients with behavioral problems.
    Hawkins JW
    J Clin Psychiatry; 1992 Mar; 53(3):101-2. PubMed ID: 1548245
    [No Abstract]   [Full Text] [Related]  

  • 26. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is vitamin E the magic bullet for the treatment of Alzheimer's disease (AD)?
    Woo K
    Perspectives; 2000; 24(1):7-10. PubMed ID: 12026332
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of selegiline in Alzheimer's patients with behavior problems.
    Goad DL; Davis CM; Liem P; Fuselier CC; McCormack JR; Olsen KM
    J Clin Psychiatry; 1991 Aug; 52(8):342-5. PubMed ID: 1907964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
    N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mild cognitive impairment].
    Nakano N; Hatakeyama Y; Yoshida T
    Ryoikibetsu Shokogun Shirizu; 2003; (40):193-6. PubMed ID: 14626099
    [No Abstract]   [Full Text] [Related]  

  • 32. High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age.
    Mangialasche F; Kivipelto M; Mecocci P; Rizzuto D; Palmer K; Winblad B; Fratiglioni L
    J Alzheimers Dis; 2010; 20(4):1029-37. PubMed ID: 20413888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose vitamin E may slow Alzheimer's decline.
    Harv Mens Health Watch; 2014 Mar; 18(8):8. PubMed ID: 24839661
    [No Abstract]   [Full Text] [Related]  

  • 34. Brain cholinesterases: III. Future perspectives of AD research and clinical practice.
    Shen ZX
    Med Hypotheses; 2004; 63(2):298-307. PubMed ID: 15236794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why vitamin E therapy fails for treatment of Alzheimer's disease.
    Brewer GJ
    J Alzheimers Dis; 2010; 19(1):27-30. PubMed ID: 20061623
    [No Abstract]   [Full Text] [Related]  

  • 36. [The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials].
    Kwieciński H; Janik P; Jamrozik Z; Opuchlik A
    Neurol Neurochir Pol; 2001; 35(1 Suppl):101-6. PubMed ID: 11732275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2.
    Pham DQ; Plakogiannis R
    Ann Pharmacother; 2005 Dec; 39(12):2065-72. PubMed ID: 16288072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
    Parkinson Study Group
    N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.